The primary endpoint of the phase III study is 3-year overall survival measured from randomisation. Secondary endpoints are 5-year overall survival, progression-free survival, procedure related characteristics (i.e. operative time, blood loss), peritoneal cancer index (PCI) score, completeness of cytoreduction (CC) score, major postoperative complications (Clavien-Dindo grade III-V) at 90-days postoperatively, hospital stay, quality of life, cost-effectiveness, and blood and tissue collection for future translational research purposes. In the experimental arm, additional secondary endpoints are severe systemic therapy-related toxicity (NCICTCAE v4.0 grade III-V), and the number of patients with progression, stable disease, and response to neoadjuvant combination chemotherapy plus bevacizumab.